The elixir of life could be developed technologically by investing $ 100 million in a life sciences company called Juvenescence in collaboration with drug developers and artificial intelligence experts, to find treatments and techniques to treat age-related diseases and increase human longevity.
The company announced successful completion of the $ 100 million Group B tour, bringing the total to $ 165 million raised by the company in 18 months.
Dr Greg Bailey, CEO of the company, said: “We have added important people to the Juvenescence team who will take our modified drugs to our times”.
The company said that recent advances in science have greatly improved our understanding of the biology of aging and seeks to develop treatments with the potential to slow, stop or reverse the elements of aging.
Jim Mellon, President of the company, said: “We have hired a group of advanced shareholders from around the world to further our common mission of improving a healthy human life”.